Design of Selective PAK1 Inhibitor G-5555: Improving Properties by Employing an Unorthodox Low-pK a Polar Moiety.

No abstract is available for this paper.

• Publication year

  2015

• Venue

  ACS Medicinal Chemistry Letters

• Publication date

  2015-11-03

• Fields of study

  Medicine, Chemistry

• Identifiers
  DOI 10.1021/acsmedchemlett.5b00398PMID 26713112PMCID PMC4677365
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Structure-Guided Design of Group I Selective p21-Activated Kinase Inhibitors.

  2015cited by this paper
• Applications of Fluorine in Medicinal Chemistry.

  2015cited by this paper
• Inhibitors of p21-activated kinases (PAKs).

  2015cited by this paper
• Small molecule inhibition of group I p21-activated kinases in breast cancer induces apoptosis and potentiates the activity of microtubule stabilizing agents

  2015cited by this paper
• Tuning HERG out: antitarget QSAR models for drug development.

  2014cited by this paper
• PAK signalling during the development and progression of cancer

  2013cited by this paper
• PAK family kinases

  2012cited by this paper
• Impact of lipophilic efficiency on compound quality.

  2012cited by this paper
• Targeting p21-activated kinase 1 (PAK1) to induce apoptosis of tumor cells

  2011cited by this paper
• A risk assessment of human ether-a-go-go-related gene potassium channel inhibition by using lipophilicity and basicity for drug discovery.

  2011cited by this paper
• The role of prostacyclin synthase and thromboxane synthase signaling in the development and progression of cancer.

  2010cited by this paper
• Small-molecule p21-activated kinase inhibitor PF-3758309 is a potent inhibitor of oncogenic signaling and tumor growth

  2010cited by this paper
• Pharmacological Promiscuity: Dependence on Compound Properties and Target Specificity in a Set of Recent Roche Compounds

  2009cited by this paper
• Tuning out of hERG.

  2008cited by this paper
• Toward the development of chemoprevention agents (III): synthesis and anti-inflammatory activities of a new class of 5-glycylamino-2-substituted-phenyl-1,3-dioxacycloalkanes.

  2008cited by this paper
• Relationships between preclinical cardiac electrophysiology, clinical QT interval prolongation and torsade de pointes for a broad range of drugs: evidence for a provisional safety margin in drug development.

  2003cited by this paper

• A kinome inhibitor screen implicates adhesion and growth factor signaling in cellular recovery after caspase activation

  2026cites this paper
• Identification of Potential Selective PAK4 Inhibitors Through Shape and Protein Conformation Ensemble Screening and Electrostatic-Surface-Matching Optimization

  2025cites this paper
• A critical role of FAK signaling in Rac1-driven melanoma cell resistance to MAPK pathway inhibition

  2025cites this paper
• Identification of a p21-activated kinase 1 (PAK1) inhibitor with 10-fold selectivity against PAK2.

  2025cites this paper
• Combined Computational Techniques for Discovery of Novel Pyrazolo[3,4‐d]pyrimidine Derivatives as PAK1 Inhibitors

  2025cites this paper
• Identifying and targeting key driver genes for collagen production within the 11q13/14 breast cancer amplicon.

  2025cites this paper
• Regulation of Vascular Injury and Repair by P21-Activated Kinase 1 and P21-Activated Kinase 2: Therapeutic Potential and Challenges

  2024cites this paper
• PAK2 as a therapeutic target in cancer: Mechanisms, challenges, and future perspectives.

  2024cites this paper
• Development of Selective Pyrido[2,3-d]pyrimidin-7(8H)-one-Based Mammalian STE20-Like (MST3/4) Kinase Inhibitors.

  2024cites this paper
• Shifting the selectivity of pyrido[2,3-d]pyrimidin-7(8H)-one inhibitors towards the salt-inducible kinase (SIK) subfamily

  2023cites this paper
• RHOAL57V drives the development of diffuse gastric cancer through IGF1R-PAK1-YAP1 signaling

  2023cites this paper
• Small Molecule Inhibitors Targeting the "Undruggable" Survivin: The Past, Present, and Future from a Medicinal Chemist's Perspective.

  2023cites this paper
• Inhibition of PAK1 generates an ameliorative effect on MPLW515L mouse model of myeloproliferative neoplasms by regulating the differentiation and survival of the megakaryocytes.

  2023cites this paper
• Identification of a novel PAK1/HDAC6 dual inhibitor ZMF-23 that triggers tubulin-stathmin regulated cell death in triple negative breast cancer.

  2023cites this paper
• Using ChEMBL to Complement Schistosome Drug Discovery

  2023influential citation
• Targeting P21-Activated Kinase-1 for Metastatic Prostate Cancer

  2023cites this paper
• The multiple roles of salt-inducible kinases in regulating physiology

  2023cites this paper
• Nutraceutical Importance of Dietary Curcumin, Its Analogues in Restricting Melanoma Growth and Modulation of Multiple Targets

  2022cites this paper
• The trilogy of P21 activated kinase, autophagy and immune evasion in pancreatic ductal adenocarcinoma.

  2022cites this paper
• Development and utility of a PAK1-selective degrader

  2022cites this paper
• The role of cell division control protein 42 in tumor and non-tumor diseases: A systematic review

  2022cites this paper
• p21-Activated kinase 1 (PAK1) in aging and longevity: An overview.

  2021cites this paper
• PAK1 Positively Regulates Oligodendrocyte Morphology and Myelination

  2021cites this paper
• Structure-based design of selective salt-inducible kinase (SIK) inhibitors

  2021cites this paper
• PAK1 inhibition reduces tumor size and extends the lifespan of mice in a genetically engineered mouse model of Neurofibromatosis Type 2 (NF2).

  2021cites this paper
• Structure-Based Design of Selective Salt-Inducible Kinase Inhibitors.

  2021cites this paper
• Geminal Diheteroatomic Motifs: Some Applications of Acetals, Ketals, and Their Sulfur and Nitrogen Homologues in Medicinal Chemistry and Drug Design.

  2021cites this paper
• Identification of a Series of N-Methylpyridine-2-carboxamides as Potent and Selective Inhibitors of the Second Bromodomain (BD2) of the Bromo and Extra Terminal Domain (BET) Proteins.

  2021cites this paper
• Optimization of a Series of 2,3-Dihydrobenzofurans as Highly Potent, Second Bromodomain (BD2)-Selective, Bromo and Extra-Terminal Domain (BET) Inhibitors.

  2021cites this paper
• The Small-Molecule Inhibitor MRIA9 Reveals Novel Insights into the Cell Cycle Roles of SIK2 in Ovarian Cancer Cells

  2021cites this paper
• Optimization of TopoIV Potency, ADMET Properties, and hERG Inhibition of 5-Amino-1,3-dioxane-Linked Novel Bacterial Topoisomerase Inhibitors: Identification of a Lead with In Vivo Efficacy against MRSA.

  2021cites this paper
• WaterMap and Molecular Dynamic Simulation-Guided Discovery of Potential PAK1 Inhibitors Using Repurposing Approaches

  2021cites this paper
• Novel Bacterial Topoisomerase Inhibitors (NBTIs) – A comprehensive review

  2021cites this paper
• Group I PAKs in myelin formation and repair of the central nervous system: what, when, and how

  2021cites this paper
• A novel PAK4 inhibitor suppresses pancreatic cancer growth and enhances the inhibitory effect of gemcitabine

  2021cites this paper
• Targeting Rho GTPase Signaling Networks in Cancer

  2020cites this paper
• Design and synthesis of 1H-indazole-3-carboxamide derivatives as potent and selective PAK1 inhibitors with anti-tumour migration and invasion activities.

  2020cites this paper
• GSK973 Is an Inhibitor of the Second Bromodomains (BD2s) of the Bromodomain and Extra-Terminal (BET) Family.

  2020cites this paper
• Computational insight into the mechanisms of action and selectivity of Afraxis PAK inhibitors.

  2020cites this paper
• P21-Activated Kinase 1: Emerging biological functions and potential therapeutic targets in Cancer

  2020cites this paper
• PAK1 inhibitor IPA-3 mitigates metastatic prostate cancer-induced bone remodeling.

  2020cites this paper
• Sterically stabilized liposomes targeting P21 (RAC1) activated kinase-1 and secreted phospholipase A2 suppress prostate cancer growth and metastasis

  2020cites this paper
• Phosphorylation-dependent activity-based conformational changes in P21-activated kinase family members and screening of novel ATP competitive inhibitors

  2019cites this paper
• MAPK- and AKT-activated thyroid cancers are sensitive to group I PAK inhibition.

  2019cites this paper
• 1,3-Dioxane-Linked Bacterial Topoisomerase Inhibitors with Enhanced Antibacterial Activity and Reduced hERG Inhibition.

  2019cites this paper
• Solution structures and biophysical analysis of full-length group A PAKs reveal they are monomeric and auto-inhibited in cis

  2019cites this paper
• Mislocalized cytoplasmic p27 activates PAK1‐mediated metastasis and is a prognostic factor in osteosarcoma

  2019cites this paper
• Combined inhibition of Aurora A and p21-activated kinase 1 as a new treatment strategy in breast cancer

  2019cites this paper
• A CRISPR screen identifies MAPK7 as a target for combination with MEK inhibition in KRAS mutant NSCLC

  2018cites this paper
• PAK4 crystal structures suggest unusual kinase conformational movements.

  2018cites this paper
• Regulating Cdc42 and Its Signaling Pathways in Cancer: Small Molecules and MicroRNA as New Treatment Candidates

  2018influential citation
• Inhibitors of the p21 Activated Kinases

  2018cites this paper
• Neurofibromatosis type 1 as a model system to study molecular mechanisms of autism spectrum disorder symptoms.

  2018cites this paper
• Group I Paks are essential for epithelial- mesenchymal transition in an Apc-driven model of colorectal cancer

  2018cites this paper
• Probing the chemical–biological relationship space with the Drug Target Explorer

  2018cites this paper
• Synthesis and anti-staphylococcal activity of novel bacterial topoisomerase inhibitors with a 5-amino-1,3-dioxane linker moiety.

  2018cites this paper
• Structure, biochemistry, and biology of PAK kinases.

  2017cites this paper
• Targeting Group I p21-Activated Kinases to Control Malignant Peripheral Nerve Sheath Tumor Growth and Metastasis

  2017cites this paper
• The Group I Pak inhibitor Frax-1036 sensitizes 11q13-amplified ovarian cancer cells to the cytotoxic effects of Rottlerin

  2017cites this paper
• Paving the Rho in cancer metastasis: Rho GTPases and beyond.

  2017cites this paper
• Choose and Use Your Chemical Probe Wisely to Explore Cancer Biology

  2017cites this paper
• p27Kip1 promotes invadopodia turnover and invasion through the regulation of the PAK1/Cortactin pathway

  2017influential citation
• From bench (laboratory) to bed (hospital/home): How to explore effective natural and synthetic PAK1-blockers/longevity-promoters for cancer therapy.

  2017cites this paper
• Targeting PAK1.

  2017cites this paper
• Synthesis and evaluation of a series of 4-azaindole-containing p21-activated kinase-1 inhibitors.

  2016cites this paper
• Targeting p21 activated kinase 1 (Pak1) to PAKup Pancreatic Cancer

  2016cites this paper
• Chemically Diverse Group I p21-Activated Kinase (PAK) Inhibitors Impart Acute Cardiovascular Toxicity with a Narrow Therapeutic Window.

  2016cites this paper
• Optimization of Highly Kinase Selective Bis-anilino Pyrimidine PAK1 Inhibitors.

  2016cites this paper
• How to stop (some) acetals hydrolysing.

  2015cites this paper